Form 8-K - Current report:
SEC Accession No. 0001140361-24-044363
Filing Date
2024-10-28
Accepted
2024-10-28 08:22:47
Documents
15
Period of Report
2024-10-24
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ef20037633_8k.htm   iXBRL 8-K 30309
2 EXHIBIT 3.1 ef20037633_ex3-1.htm EX-3.1 7721
3 EXHIBIT 3.2 ef20037633_ex3-2.htm EX-3.2 133344
  Complete submission text file 0001140361-24-044363.txt   346918

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA grce-20241024.xsd EX-101.SCH 3976
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE grce-20241024_lab.xml EX-101.LAB 22691
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE grce-20241024_pre.xml EX-101.PRE 16548
18 EXTRACTED XBRL INSTANCE DOCUMENT ef20037633_8k_htm.xml XML 4393
Mailing Address 103 CARNEGIE CENTER SUITE 300 PRINCETON NJ 08540
Business Address 103 CARNEGIE CENTER SUITE 300 PRINCETON NJ 08540 609-322-1602
Grace Therapeutics, Inc. (Filer) CIK: 0001444192 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-35776 | Film No.: 241398480
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)